* Novartis receives approval for first malaria medicine for newborn babies and young infants - ...

Kenya’s official first-line treatment for uncomplicated malaria is Artemether-Lumefantrine, a combination of two drug ...

Your premium access has ended, but the best of Nation.Africa is still within reach. Renew now to unlock exclusive stories and in-depth features. Reclaim your full access. Click below to renew.

CHENNAI: Swiss-pharma major Novartis AG said early this week that its pediatric malaria treatment, Coartem Baby, received regulatory approval from Swissmedic, Switzerland's national medicines ...

The Swissmedic approval is based on the Phase II/III CALINA study, which investigated a new ratio and dose of Coartem (artemether-lumefantrine) to account for metabolic differences in babies under 5 ...

According to the alert, stability studies have shown that once reconstituted, the Artemether/Lumefantrine oral suspension becomes unstable, which can result in a loss of efficacy.

According to the alert, stability studies have shown that once reconstituted, the Artemether/Lumefantrine oral suspension becomes unstable, which can result in a loss of efficacy. The agency said this ...

Artemether and Lumefantrine Medication Information Learn everything you need to know about Artemether and Lumefantrine-pronunciation, uses, dosage guidelines, indications, and when to take or ...

Coartem (Artemether Lumefantrine) is a drug used to treat malaria. It is a combination of two drugs, artemether and lumefantrine, that work together to kill malaria in the blood. Coartem is usually ...